Clinicopathologic Features and Clinical Outcome Differences in De Novo Versus Secondary Histiocytic Sarcomas: A Multi-institutional Experience and Review of the Literature
ConclusionThe shorter overall survival with secondary HS suggests a more aggressive course than that with de novo disease. Larger scale studies are needed to further investigate the biology and genetics of HS.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
More News: Biology | Cancer & Oncology | Chemotherapy | Databases & Libraries | Genetics | Hematology | Jordan Health | Leukemia | Lymphoma | Mexico Health | Middle East Health | Myeloma | Sarcomas | Study